{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T19:21:21Z","timestamp":1775503281475,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"20","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Swiss Sanfilippo Foundation"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.bmc.2018.09.023","type":"journal-article","created":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T20:17:12Z","timestamp":1537561032000},"page":"5462-5469","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["4-epi-Isofagomine derivatives as pharmacological chaperones for the treatment of lysosomal diseases linked to \u03b2-galactosidase mutations: Improved synthesis and biological investigations"],"prefix":"10.1016","volume":"26","author":[{"given":"Sophie","family":"Front","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofia","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Zoete","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Charollais-Thoenig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Estelle","family":"Gallienne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9line","family":"Marmy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7994-0916","authenticated-orcid":false,"given":"Vincent","family":"Pilloud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6308-4908","authenticated-orcid":false,"given":"Roger","family":"Marti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier R.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Demotz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2018.09.023_b0005","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ymgme.2008.04.012","article-title":"GM1 gangliosidosis: review of clinical, molecular, and therapeutic aspects","volume":"94","author":"Brunetti-Pierri","year":"2008","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.bmc.2018.09.023_b0010","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.bbadis.2011.03.018","article-title":"GM1 gangliosidosis and Morquio B disease: an update on genetic alterations and clinical findings","volume":"1812","author":"Caciotti","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.bmc.2018.09.023_b0015","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/mt.2015.62","article-title":"Pharmacological chaperone therapy: preclinical development, clinical translation, and prospects for the treatment of lysosomal storage disorders","volume":"23","author":"Parenti","year":"2015","journal-title":"Mol Ther"},{"key":"10.1016\/j.bmc.2018.09.023_b0020","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1750-1172-7-91","article-title":"Safety and pharmacodynamic effects of a pharmacological chaperone on \u03b1-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies","volume":"7","author":"Germain","year":"2012","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.bmc.2018.09.023_b0025","doi-asserted-by":"crossref","first-page":"15912","DOI":"10.1073\/pnas.2536657100","article-title":"Chemical chaperone therapy for brain pathology in GM1-gangliosidosis","volume":"100","author":"Matsuda","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bmc.2018.09.023_h0030","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejmech.2016.09.095","volume":"126","author":"Front","year":"2017","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2018.09.023_h0035","unstructured":"Martin OR, Gallienne E, Front S, Charollais J, Demotz S. 4-Epi-isofagomine derivatives. Eur Pat Appl. 15165465, April 28, 2015."},{"key":"10.1016\/j.bmc.2018.09.023_b0035","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.carres.2016.03.020","article-title":"Synthesis of C-5a-substituted derivatives of 4-epi-isofagomine: notable \u03b2-galactosidase inhibitors and activity promotors of GM1-gangliosidosis related human lysosomal \u03b2-galactosidase mutant R201C","volume":"429","author":"Thonhofer","year":"2016","journal-title":"Carbohydr Res"},{"key":"10.1016\/j.bmc.2018.09.023_b0040","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.bmcl.2016.01.059","article-title":"Synthesis of C-5a-chain extended derivatives of 4-epi-isofagomine: powerful \u03b2-galactosidase inhibitors and low concentration activators of GM1-gangliosidosis-related human lysosomal \u03b2-galactosidase","volume":"26","author":"Thonhofer","year":"2016","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2018.09.023_b0045","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.carres.2017.03.003","article-title":"A Morita-Baylis-Hillman based route to C-5a-chain-extended 4-epi-isofagomine type glycosidase inhibitors","volume":"442","author":"Lebl","year":"2017","journal-title":"Carbohydr Res"},{"key":"10.1016\/j.bmc.2018.09.023_b0050","doi-asserted-by":"crossref","first-page":"4903","DOI":"10.1016\/j.tetlet.2004.04.121","article-title":"Synthesis of novel 1-N-iminosugars from chiral nonracemic bicyclic lactams","volume":"45","author":"Xie","year":"2004","journal-title":"Tetrahedron Lett"},{"key":"10.1016\/j.bmc.2018.09.023_b0055","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1021\/ja973443k","article-title":"1-N-Iminosugars: potent and selective inhibitors of \u00b7\u03b2-glycosidases","volume":"120","author":"Ichikawa","year":"1998","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.bmc.2018.09.023_b0060","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/cmdc.201500485","article-title":"N-Alkyl-, 1-C-alkyl-, and 5-C-alkyl-1,5-dideoxy-1,5-imino-(l)-ribitols as galactosidase inhibitors","volume":"11","author":"Front","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmc.2018.09.023_h6320","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1016\/S0040-4020(01)87008-3","article-title":"Simple approach to O-protected deaminotunicaminyluracil","volume":"50","author":"Karpiesiuk","year":"1994","journal-title":"Tetrahedron"},{"key":"10.1016\/j.bmc.2018.09.023_h0075","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1016\/0040-4039(95)00483-S","article-title":"Benzyl 2,3-O-isopropylidene-\u03b2-D-ribo-l,4-pentodialdofuranoside as a D-ribose chiron for the synthesis of terpenyl tetraols and aminotriols","volume":"36","author":"Duvold","year":"1995","journal-title":"Tetrahedron Lett"},{"key":"10.1016\/j.bmc.2018.09.023_b0070","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0065-2318(08)60400-X","article-title":"The Use of Carbohydrates in the Synthesis and Configurational Assignments of Optically Active, Non-Carbohydrate Compounds","volume":"27","author":"Inch","year":"1972","journal-title":"Adv Carbohydr Chem Biochem"},{"key":"10.1016\/j.bmc.2018.09.023_b0075","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1055\/s-1994-25625","article-title":"Meerwein\u2013Ponndorf\u2013Verley reductions and Oppenauer oxidations: an integrated approach","author":"De Graauw","year":"1994","journal-title":"Synthesis"},{"key":"10.1016\/j.bmc.2018.09.023_b0080","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J Comput Chem"},{"key":"10.1016\/j.bmc.2018.09.023_b0085","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J Comput Chem"},{"key":"10.1016\/j.bmc.2018.09.023_b0090","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/jcc.24249","article-title":"Attracting cavities for docking. Replacing the rough energy landscape of the protein by a smooth attracting landscape","volume":"37","author":"Zoete","year":"2016","journal-title":"J Comput Chem"},{"key":"10.1016\/j.bmc.2018.09.023_b0095","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1002\/cmdc.201402411","article-title":"Iminosugar-based galactoside mimics as inhibitors of galactocerebrosidase: SAR studies and comparison with other lysosomal galactosidases","volume":"9","author":"Biela-Banas","year":"2017","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmc.2018.09.023_b0100","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ab.2007.05.016","article-title":"Analytical method for the determination of disaccharides derived from keratan, heparan, and dermatan sulfates in human serum and plasma by high-performance liquid chromatography\/turbo ionspray ionization tandem mass spectrometry","volume":"368","author":"Oguma","year":"2007","journal-title":"Anal Biochem"},{"key":"10.1016\/j.bmc.2018.09.023_b0105","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s10545-009-1077-0","article-title":"The pharmacological chaperone 1-deoxygalactonojirimycin increases \u03b1-galactosidase A levels in Fabry patient cell lines","volume":"32","author":"Benjamin","year":"2009","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.bmc.2018.09.023_b0110","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1107\/S0021889808042726","article-title":"OLEX2: a complete structure solution, refinement, and analysis program","volume":"42","author":"Dolomanov","year":"2009","journal-title":"J Appl Cryst"},{"key":"10.1016\/j.bmc.2018.09.023_b0115","first-page":"3","article-title":"SHELXT \u2013 integrated space-group and crystal structure determination","volume":"A71","author":"Sheldrick","year":"2015","journal-title":"Acta Cryst"},{"key":"10.1016\/j.bmc.2018.09.023_b0120","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/nar\/28.1.235","volume":"28","author":"Berman","year":"2000","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.bmc.2018.09.023_b0125","doi-asserted-by":"crossref","first-page":"14560","DOI":"10.1074\/jbc.M113.529529","article-title":"Structural basis of pharmacological chaperoning for human \u03b2-galactosidase","volume":"289","author":"Suzuki","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2018.09.023_b0130","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ymgme.2012.06.007","article-title":"Evaluation of N-nonyl-deoxygalactonojirimycin as a pharmacological chaperone for human GM1 gangliosidosis leads to identification of a feline model suitable for testing enzyme enhancement therapy","volume":"107","author":"Rigat","year":"2012","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.bmc.2018.09.023_b0135","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0003-2697(03)00056-3","article-title":"Analysis of a glucose tetrasaccharide elevated in Pompe disease by stable isotope dilution-electrospray ionization tandem mass spectrometry","volume":"316","author":"Young","year":"2003","journal-title":"Anal Biochem"},{"key":"10.1016\/j.bmc.2018.09.023_b0140","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1006\/abio.2000.4838","article-title":"Liquid chromatographic assay for a glucose tetrasaccharide, a putative biomarker for the diagnosis of Pompe disease","volume":"287","author":"An","year":"2000","journal-title":"Anal Biochem"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089618313725?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089618313725?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T00:59:25Z","timestamp":1760835565000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089618313725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":30,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S0968089618313725"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2018.09.023","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"4-epi-Isofagomine derivatives as pharmacological chaperones for the treatment of lysosomal diseases linked to \u03b2-galactosidase mutations: Improved synthesis and biological investigations","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2018.09.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}